Myocardial InjuryNCT07125612
Impact of Perioperative Allogeneic Red Blood Cell Transfusion on Postoperative Myocardial Injury After Liver Resection
An observational study of Myocardial Injury and Acuter Kidney Injury, run by Hao Li.
Trial summary
We aimed to explore the influence of ABT on the incidence of MINS, AKI, and overall prognosis among advanced-age HCC patients who underwent hepatectomy Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Myocardial Injury, Acuter Kidney Injury
- How many people
- 487 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2016to 1 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: age ≥65 years old patients
Who may be able to join
- Patients over 65 years with HCC undergoing elective surgery between January 2016 and December 2018
Who cannot join
- ASA grade V requiring repeat surgery within 1 week losing to follow-up and/or those with >5% missing data
About this study
We aimed to explore the influence of ABT on the incidence of MINS, AKI, and overall prognosis among advanced-age HCC patients who underwent hepatectomy
- Conditions
- Myocardial Injury, Acuter Kidney Injury
- Keywords
- perioperative allogeneic red blood cell transfusion, elderly surgical patients
What is being measured
The primary outcome is the main question the study is designed to answer.
the incidence of MINS within postoperative 30 days
Measured: postoperative day 1-30
Secondary outcomes (2)
overall survival (OS)
the time from the date of surgery to the date of death
Measured: postoperative day 1-30
postoperative 7-day AKI
Measured: postoperative day 1-7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Aug 2025
- Study start1 Jan 2016
- Primary completion31 Dec 2018
- Study completion1 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 487 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hao Li
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Hao Li, Chinese PLA General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07125612
- Sponsor's protocol ID
- ChinaPLAGH_transfusion
- Status last verified
- Aug 2025
- First submitted
- 9 Aug 2025
- Last updated
- 15 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Perioperative Allogeneic Red Blood Cell Transfusion on Postoperative Myocardial Injury After Liver Resection
- ClinicalTrials.gov ID
- NCT07125612
- Acronym / sponsor ID
- ChinaPLAGH_transfusion
- Conditions
- Myocardial Injury, Acuter Kidney Injury
- Keywords
- perioperative allogeneic red blood cell transfusion, elderly surgical patients
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 487 participants (actual)
- Lead sponsor
- Hao LiUniversity, hospital or other
- Study start
- 1 Jan 2016 (actual)
- Primary completion
- 31 Dec 2018 (actual)
- Study completion
- 1 Jun 2025 (actual)
- First posted
- 15 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We aimed to explore the influence of ABT on the incidence of MINS, AKI, and overall prognosis among advanced-age HCC patients who underwent hepatectomy
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- age ≥65 years old patients
Key inclusion criteria (1 listed)
- Patients over 65 years with HCC undergoing elective surgery between January 2016 and December 2018
Key exclusion criteria (1 listed)
- ASA grade V requiring repeat surgery within 1 week losing to follow-up and/or those with >5% missing data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
the incidence of MINS within postoperative 30 days
Time frame: postoperative day 1-30
2 secondary outcomes
overall survival (OS)
Time frame: postoperative day 1-30
postoperative 7-day AKI
Time frame: postoperative day 1-7
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2025.
- Individual participant dataSharing planned: No
Related trials for Myocardial Injury
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
Not yet recruitingObservational study
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Heart Failure, Coronary Artery Disease
Not yet recruitingPhase 2
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
RecruitingObservational study
Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Injury and Acuter Kidney Injury, run by Hao Li.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the incidence of MINS within postoperative 30 days (time frame: postoperative day 1-30). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2025.